- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03383939
Inhaled A1AT in Adult Stable Bronchiectasis
Effects of Inhaled Alpha-1-anti-trypsin on Proteolytic Activity in BAL of Bronchiectasis Patients With Chronic Bronchial Expectoration
Aim: to investigate the influence of alpha1-antitrypsin (A1-AT) nebulization on levels of A1-AT in BAL and plasma in patients with stable bronchiectasis.
Method: single-blind placebo-controlled randomised clinical trial. 19 stable bronchiectasis patients with chronic bronchial infection and 10 control patients (without bronchiectasis) underwent a bronchoscopy in order to assess levels and inhibitory capacity of A1AT and neutrophilic elastase. Afterwards, the 19 bronchiectasis patients were randomly allocated to receive inhaled A1AT 250mg diluted in 10ml 0.9% saline solution once a day for a month (Group A, n: 10) or placebo (10ml 0.9% saline solution; group B, n: 9). A new BAL was performed in both groups (A and B) 24 hours after the end of treatment (1month) to re-analyze A1AT and NE.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Effects of inhaled alpha-1-anti-trypsin in bronchiectasis patients with chronic bronchial infection.
Introduction: one of the main features of bronchiectasis is chronic and deregulated neutrophilic bronchial inflammation. Excessive neutrophilic elastase (NE) activity has been widely described as part of the characteristic imbalance between proteases and anti-proteolytic enzymes that characterizes airways inflammation and progressive lung damage in bronchiectasis.
Alpha-1-antitrypsin (A1AT) is a protease inhibitor involved in protecting lung tissue from enzymes of inflammatory cells, including neutrophilic elastase, and its concentration rises in case of acute and chronic inflammation. Its reduction or absence is associated with the development of a specific kind of emphysema in case of exposure to tobacco smoking.
Moreover it is likely that its levels could be reduced in bronchiectasis as a consequence of chronic bronchial infection and inflammatory deregulation.
Aims:
- concentrations of total and free NE, NE inhibitory capacity and A1AT levels were investigated in broncho-alveolar lavage (BAL) of bronchiectasis patients with chronic airways infection in stable conditions in comparison with a control group (patients without bronchiectasis)
- The effects of inhaled A1AT (Prolastin) on BAL concentration of total and free NE and A1AT and inhibitory capacity of NE were assessed after one month of treatment in patients with bronchiectasis and chronic bronchial infection (placebo controlled trial) Study design: simple blind placebo-controlled randomized clinical trial
Methods:
19 patients with stable non cystic fibrosis bronchiectasis and chronic bronchial infection and 10 patients without bronchiectasis (control group) underwent a bronchoscopy to perform BAL analysis.
The 19 bronchiectasis patients were randomly allocated to receive inhaled A1AT 250mg diluted in 10ml 0.9% saline solution once a day for a month (Group A, n: 10) or placebo (10ml 0.9% saline solution; group B, n: 9). A new BAL was performed in both groups (A and B) 24 hours after the end of treatment (1month) to re-analyze A1AT and NE.
Clinical, microbiological, biochemical, functional and radiological characteristics of bronchiectasis and potential side effects of treatment on both arms were also recorded before (baseline), at 7, 15, 30 days of treatment and at 1 and 2 months follow-up visits after the end of treatment. The trial was approved by Spanish Ministry of Health (Trial nº 95/256) and local Ethics Committee (AC(HG) 44/95) and all patients signed written consent.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stable clinical conditions (no use of systemic antibiotic or steroid treatment in the last month)
- diagnosis of bronchiectasis bt CT scan
- chronic purulent or mucopurulent expectoration (daily sputum expectoration in the last 6 months or more)
Exclusion Criteria:
- Cystic fibrosis
- interstitial lung disease as cause of bronchiectasis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: group A
10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month. Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month |
one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month.
A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
Other Names:
|
Placebo Comparator: group B
9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month. intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month. |
10ml of 0.9% NaCl saline solution nebulised once daily for 1 month.
A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
Other Names:
|
No Intervention: Control
10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline BAL levels of A1AT
Time Frame: 1 MONTH
|
Changes from baseline in levels of A1AT in broncho-alveolar lavage at 1 month of treatment with inhaled A1AT
|
1 MONTH
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline neutrophil elastase in BAL
Time Frame: 1 month
|
Changes from baseline in levels of neutrophil elastase in broncho-alveolar lavage at 1 month of treatment with inhaled A1AT
|
1 month
|
Changes from baseline neutrophil elastase inhibitory capacity in BAL
Time Frame: 1 month
|
Changes from baseline in levels of neutrophil elastase inhibitory capacity in broncho-alveolar lavage at 1 month of treatment with inhaled A1AT
|
1 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Javier De Gracia, MD, PhD, Servei de Pneumologia, Vall D'Hebron Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC(HG) 44/95
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis Adult
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedBronchiectasis AdultChina
-
Azienda Socio Sanitaria Territoriale della Valle...RecruitingCopd | Bronchiectasis AdultItaly
Clinical Trials on Group A
-
Riphah International UniversityCompletedAutism Spectrum DisorderPakistan
-
Riphah International UniversityRecruitingHemiplegic Cerebral PalsyPakistan
-
Dr. Jean-Sebastien Delisle, MD, PhDRecruitingLymphoma | Epstein-Barr Virus Infections | Post-Transplant Lymphoproliferative DisorderCanada
-
Riphah International UniversityCompleted
-
Samsung Medical CenterCompletedEmergencies | Pediatric Disorder | Femoral Artery InjuryKorea, Republic of
-
The University of Texas Health Science Center,...National Institute for Occupational Safety and Health (NIOSH/CDC)Completed
-
Kahramanmaras Sutcu Imam UniversityCompletedPain | Interleukin | Vessels; VaricoseTurkey
-
Manuel RodríguezUnknownBrain IschemiaSpain
-
Zhu WeimingRecruiting
-
Oxford University Hospitals NHS TrustUniversity Hospital Southampton NHS Foundation Trust; University Hospital BirminghamCompletedAtrial Fibrillation | Cardiac ArrhythmiaUnited Kingdom